Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial entities : Takeda pharmaceutical company limited save search
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.14%
H: 0.17%
C: -0.27%
cabometyx asco immunotherapy trial
Takeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -2.55%
H: 1.07%
C: 0.4%
trial
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
Published: 2023-09-11 (Crawled : 12:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.31%
H: 0.91%
C: 0.52%
tak-279 active positive treatment topline results study
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Published: 2023-06-20 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.25%
H: 0.31%
C: -0.12%
hyqvia meeting set trial therapy
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.06%
H: 0.53%
C: -0.31%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.26%
C: -1.77%
lancet publication results
Global Gaucher's Disease Treatment Market Research Report 2023: Emerging Therapies, Clinical Trials, Treatments, Current Scenario Evaluation, Patient Profile
Published: 2023-05-10 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -1.83%
H: 0.12%
C: -3.06%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.4%
H: 0.34%
C: 0.19%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.11%
H: 0.22%
C: -0.52%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.57%
H: 0.37%
C: -0.01%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
disease report treatment research global market
Stem Cell Therapy Global Market Report 2022: Advancements in Stem Cell Clinical Trials Fuels Growth
Published: 2023-04-05 (Crawled : 23:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.24%
H: 2.42%
C: 1.94%
report cell trials global therapy growth market
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.12%
H: 1.55%
C: 1.03%
ARWR | $22.62 0.4% 0.4% 1.3M
|
Health Technology
|
| O: 0.67%
H: 0.08%
C: -2.22%
liver disease payment milestone study
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
Published: 2023-03-30 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.67%
H: 0.89%
C: -0.06%
results study
Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting
Published: 2023-03-20 (Crawled : 14:20) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.73%
H: 0.78%
C: 0.61%
meeting trial
Global Intravenous (IV) Iron Drugs Market Report 2022: Clinical Trials, Industry Size, Share, Trends, Opportunities, and Forecasts, 2018-2028
Published: 2023-02-28 (Crawled : 03:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.13%
H: 0.13%
C: -0.13%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: -0.11%
H: 1.61%
C: -0.11%
global report market
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2023-02-13 (Crawled : 00:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -1.37%
H: 0.69%
C: 0.51%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.03%
H: 1.69%
C: 1.32%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.68%
H: 1.66%
C: 1.49%
opdivo renal trial cell carcinoma nivolumab
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Published: 2022-12-13 (Crawled : 12:20) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 2.21%
H: 0.66%
C: -0.07%
ndi-0348 acquire therapeutics potential
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
ntact-01 lung immunotherapy trial update cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
LIVTENCITY (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus (CMV) infection
Published: 2022-12-01 (Crawled : 13:20) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.75%
H: 0.57%
C: 0.2%
cytomegalovirus positive infection
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.22%
H: 1.46%
C: 1.38%
iclusig approved trial
Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials
Published: 2022-09-01 (Crawled : 13:20) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.58%
C: 0.29%
isp-001 fda clearance trials application therapy mps-ih mps-i
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.